{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:47:59Z","timestamp":1768265279754,"version":"3.49.0"},"reference-count":19,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dopamine agonists have been used in the treatment of acromegaly, but they are modestly effective and are rarely associated with impulse control disorders (ICDs). We present the case of a 34-year-old woman with acromegaly who underwent transsphenoidal resection for an invasive pituitary macroadenoma, followed by the development of panhypopituitarism. Postoperative imaging revealed residual tumor, and her insulin-like growth factor I levels remained elevated, indicating disease persistence. She subsequently received salvage radiosurgery and was treated with lanreotide and cabergoline, achieving biochemical control of her disease. The patient later reported frequent adrenal crisis episodes with worsening anxiety. Four years after initiating cabergoline, she disclosed impulse control behaviors, including pathological gambling, which had resulted in financial stress and emotional strain. Two weeks after discontinuing cabergoline, she had complete resolution of her ICD symptoms with improved anxiety levels and fewer adrenal crisis episodes. In this case, cabergoline-induced gambling contributed to psychosocial stress that likely exacerbated her adrenal crisis episodes. Our case emphasizes the need for routine behavioral screening in patients treated with dopamine agonists. Early identification and discontinuation or dose reductions of dopamine agonists is recommended to allow for ICD resolution and consequently, reducing the risk of exacerbating adrenal crisis episodes.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf263","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:15:07Z","timestamp":1762762507000},"source":"Crossref","is-referenced-by-count":1,"title":["Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-1049","authenticated-orcid":false,"given":"Mercedes","family":"Martinez-Gil","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Creighton University School of Medicine , Phoenix, AZ 85012 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadee","family":"Aghel","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine , Creighton University, Phoenix, AZ 85012 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tshibambe N","family":"Tshimbombu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute , Phoenix, AZ 85013 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-2728","authenticated-orcid":false,"given":"Kevin C J","family":"Yuen","sequence":"additional","affiliation":[{"name":"Barrow Pituitary Center, Barrow Neurological Institute , Phoenix, AZ 85013 ,","place":["USA"]},{"name":"Department of Medicine, University of Arizona College of Medicine , Phoenix, AZ 85004 ,","place":["USA"]},{"name":"Department of Medicine, Creighton University School of Medicine , Phoenix, AZ 85012 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"12","key":"2025111003150015400_luaf263-B1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2025111003150015400_luaf263-B2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025111003150015400_luaf263-B3","doi-asserted-by":"crossref","first-page":"101887","DOI":"10.1016\/j.beem.2024.101887","article-title":"Real-world value of cabergoline in the treatment of acromegaly","volume":"38","author":"Shimon","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2025111003150015400_luaf263-B4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"key":"2025111003150015400_luaf263-B5","doi-asserted-by":"crossref","first-page":"bnaf020","DOI":"10.1210\/endrev\/bnaf020","article-title":"Medical treatment of acromegaly: navigating the present, shaping the future","author":"Gadelha","year":"2025","journal-title":"Endocr Rev"},{"issue":"11","key":"2025111003150015400_luaf263-B6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1176\/appi.ajp.158.11.1783","article-title":"Psychiatric aspects of impulsivity","volume":"158","author":"Moeller","year":"2001","journal-title":"Am J Psychiatry"},{"key":"2025111003150015400_luaf263-B7","doi-asserted-by":"crossref","first-page":"844718","DOI":"10.3389\/fpsyt.2022.844718","article-title":"Binge eating and compulsive buying during cabergoline treatment for prolactinoma: a case report","volume":"13","author":"Correa E Castro","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"2025111003150015400_luaf263-B8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"issue":"6","key":"2025111003150015400_luaf263-B9","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1530\/EJE-18-0667","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?","volume":"179","author":"Barake","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025111003150015400_luaf263-B10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parkreldis.2011.01.009","article-title":"Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies","volume":"17","author":"Hassan","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"2025111003150015400_luaf263-B11","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025111003150015400_luaf263-B12","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2025111003150015400_luaf263-B13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol"},{"key":"2025111003150015400_luaf263-B14","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-025-04242-7","article-title":"Adrenal crisis: incidence, clinical presentation and risk factors in patients with Addison's disease","author":"Scala","year":"2025","journal-title":"Endocrine"},{"issue":"9","key":"2025111003150015400_luaf263-B15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra1807486","article-title":"Adrenal crisis","volume":"381","author":"Rushworth","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2025111003150015400_luaf263-B16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025111003150015400_luaf263-B17","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025111003150015400_luaf263-B18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s40266-013-0090-z","article-title":"Dopamine agonist withdrawal syndrome: implications for patient care","volume":"30","author":"Nirenberg","year":"2013","journal-title":"Drugs Aging"},{"issue":"4","key":"2025111003150015400_luaf263-B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","article-title":"Dopamine agonist-induced impulse control disorders in a patient with prolactinoma","volume":"54","author":"Almanzar","year":"2013","journal-title":"Psychosomatics"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/12\/luaf263\/65251328\/luaf263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/12\/luaf263\/65251328\/luaf263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:15:10Z","timestamp":1762762510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf263\/8317726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf263","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,27]]},"article-number":"luaf263"}}